Synfini — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Synfini is a private, pre-revenue platform company building an integrated AI and robotics-driven foundry for small-molecule drug discovery. Its technology aims to bridge the critical gap between in-silico molecular design and physical synthesis and testing, offering services and hosted AI models to external researchers and running internal discovery programs. Recent milestones include securing $8.9 million in discovery funding, being assessed as 'Awardable' for DARPA's ERIS Marketplace, and opening cloud access to its platform, positioning it as a emerging player in the AI-driven biotech space.

Oncology

Technology Platform

The Synfini Agile AI Foundry is an integrated platform combining expert-curated generative AI for molecular design and synthetic planning, hosted AI models (target-specific & ADME/Tox), organized discovery workflows, and automated physical execution via the SynBuild™ suite (high-throughput synthesis with integrated microscale purification). It aims to bridge virtual design and physical chemistry.

Opportunities

The high cost and failure rate of traditional drug discovery creates a massive market for AI and automation solutions.

Synfini's integrated 'full-stack' approach, particularly with recent innovations like in-line microscale purification, addresses critical bottlenecks, positioning it to capture value from biotechs and pharma seeking to accelerate R&D.

Opportunities also exist in government contracts, as evidenced by its DARPA 'Awardable' status.

Risk Factors

Key risks include the technical challenge of perfectly integrating AI predictions with physical lab workflows, and the risk that the platform's AI models may not generalize well across diverse targets.

The company also faces intense competition from established AI biotechs and internal pharma efforts, requiring robust validation and commercial execution to achieve market adoption.

Competitive Landscape

Synfini operates in the highly competitive AI-driven drug discovery sector, competing with pure-play AI/software companies (e.g., Schrödinger, Atomwise), integrated AI/biotech companies (e.g., Recursion, Exscientia), and large CROs investing in automation. Its differentiation lies in its tight, closed-loop integration of AI design with proprietary, automated synthesis and purification, aiming to control the entire early discovery cycle.

More companies in AI / Machine Learning →More companies in United States →